PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.65%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
44.07%
G&A change of 44.07% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
473.10%
Other expenses change of 473.10% while AXSM maintains costs. Bruce Berkowitz would investigate efficiency.
6.92%
Operating expenses growth above 1.5x AXSM's 0.00%. Michael Burry would check for inefficiency.
6.92%
Total costs growth above 1.5x AXSM's 0.00%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
473.10%
D&A change of 473.10% while AXSM maintains D&A. Bruce Berkowitz would investigate efficiency.
73.55%
EBITDA change of 73.55% while AXSM is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
-6.92%
Operating income decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
163.21%
Other expenses change of 163.21% while AXSM maintains costs. Bruce Berkowitz would investigate control.
121.05%
Income change of 121.05% while AXSM is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Income change of 121.05% while AXSM is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
121.15%
EPS change of 121.15% while AXSM is flat. Bruce Berkowitz would examine quality.
115.11%
Diluted EPS change of 115.11% while AXSM is flat. Bruce Berkowitz would examine quality.
2.25%
Share count change of 2.25% while AXSM is stable. Bruce Berkowitz would verify approach.
42.15%
Diluted share change of 42.15% while AXSM is stable. Bruce Berkowitz would verify approach.